BIOREGENX, INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$386K
↓-16.3% -$75Kvs FY2024 (Q4)
Gross Profit
$319K
↓-1.2% -$4Kvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $386K | $460K |
| COGS | $67K | $138K |
| Gross Profit | $319K | $323K |
| R&D | $32K | $0 |
| SG&A | $552K | $2M |
| D&A | $52K | $2M |
| Other OpEx | $0 | $0 |
| Operating Income | $0 | $0 |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $0 | $0 |
| Tax | $0 | $0 |
| Net Income | $0 | $0 |
QuarterCharts · SEC EDGAR data · BRGX · Comparing FY2025 (Q4) vs FY2024 (Q4)